Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unifive is a liquid pentavalent vaccine developed to provide active immunity against five major childhood diseases: diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib). It is a combination of diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis, recombinant hepatitis B surface antigen (HBsAg), and purified capsular polysaccharide of Hib conjugated to a tetanus toxoid carrier. As a fully liquid formulation, it eliminates the need for reconstitution in the field, thereby reducing the risk of contamination and administration errors. Unifive is WHO-prequalified and is primarily utilized in national immunization programs across various developing nations to improve coverage and reduce the number of injections required for infants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Unifive.